Takeda to close Deerfield HQ, move to Boston
Takeda Pharmaceuticals said today that it plans to close its headquarters in Deerfield and move to Boston.
The Deerfield site employs just under 1,000 people, said Takeda spokeswoman Julia Ellwanger. "The Deerfield closure will impact all employees who physically work out of the Deerfield site. It does not apply to field-based roles," she said. "A number of the employees currently located in the Deerfield office will be provided with job offers and/or relocation opportunities," she added.
The work currently performed at Takeda's Deerfield location will progressively consolidate from Deerfield into the greater Boston area following a successful closing of the Shire acquisition, which is subject to shareholder approvals and regulatory consents, Ellwanger said.
"This move, while difficult, will allow closer collaboration across Takeda to best position our future pipeline for success. It will also simplify our existing Takeda U.S. operations," she said.
The exact date of closing the Deerfield site is not yet known. However, it is expected that employees will be notified of their own personal outcome within six months after the Shire deal closes, Ellwanger said.
Lake County leaders learned of the move Monday evening.
Kevin Considine, president & CEO of Lake County Partners, said he informed his board of directors of the possibility that the company plans to move many of 1,000 positions to the Boston area.
"This is unfortunate, but not unexpected," he said, as the company has made several Boston-based acquisitions over the years and moved R&D to Boston last year.
The 1,000 employee number does not include roughly 900 Shire employees in Bannockburn, Considine said. "While Takeda cannot comment on those positions until the deal closes, it is unlikely that the Bannockburn site would remain. Small production teams in Round Lake Beach and Barrington might remain," Considene said.
"It's disappointing. Takeda has been a good corporate citizen," he said Tuesday morning.
Other local pharma companies will be eager to snatch up that talent. "We firmly believe in our talent pool," Considene said.
"But this is still a significant loss," he said.